Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Apple Turns 50: From Garage Startup to AI Crossroads 
RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2017 -- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that Chief Executive Officer Mark Velleca, MD, PhD, will present a company overview at the 35th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, January 10, at 9 a.m. PT at The Westin St. Francis Hotel in San Francisco.
About G1 Therapeutics, Inc.
G1 Therapeutics is a clinical-stage oncology company developing novel, small-molecule therapies that address significant unmet needs in people with cancer. The company is advancing a pipeline of potential best-in-class and first-in-class drug candidates in multiple oncology indications. G1 is privately held and based in Research Triangle Park, NC.
Visit www.g1therapeutics.com for more information.
Contact: Mark Velleca, MD, PhD G1 Therapeutics 919-213-9838 [email protected] Investors: Robert Uhl Westwicke Partners 858-356-5932 [email protected] Media: Laura Bagby 6 Degrees Communications 312-448-8098 [email protected]
